# US 2026/0091137 A1 · Retron directed gene editing

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0091137 A1
- Document ID: US20260091137A1
- Status: Published application
- Kind: A1
- Application number: 19/111,662
- Filed: 2023-09-15
- Published: 2026-04-02
- Earliest claimed: 2022-09-15
- Assignees: Enceladus Bio, Inc.
- Applicants: Enceladus Bio, Inc.
- Inventors: Brian Busser; Johann Neil Reshan Cooke; Robin L. Armstrong; Gregory Mazo; Glenn Christopher Tan; Madyson Scherr
- Web page: https://patentgrep.com/patent/US20260091137A1

## CPC

- A61K 48/0058: {Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct}
- C12N 15/907: {in mammalian cells}
- C12N 9/1276: {RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase}
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/85: for animal cells
- C07K 2319/09: containing a nuclear localisation signal
- C07K 2319/80: containing a DNA binding domain, e.g. Lacl or Tet-repressor
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2800/107: for mammalian
- C12N 2800/22: Vectors comprising a coding region that has been codon optimised for expression in a respective host
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Compounds, polypeptides, compositions, and nucleic acid molecules are provided herein that can be used, for example, to edit the genome of a cell, such as a human cell.

## Claims

### Claim 1

A method of modifying, or inducing one or more sequence modifications in one or more target nucleic acids of interest at one or more target loci within a genome of a host cell, such as a mammalian cell, the method comprising:
(a) transforming the host cell with one or more vectors encoding a heterologous nucleic acid molecule and a guide RNA (gRNA), wherein the heterologous nucleic acid molecule comprises a first inverted repeat nucleic acid molecule sequence upstream of a coding region and a second inverted repeat nucleic acid molecule sequence downstream of the coding region, wherein the coding region comprises a nucleic acid molecule comprising:
(i) an msr locus and an msd locus comprising the nucleic acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to any one of SEQ ID NO: 1, or 2; and
(ii) a donor DNA sequence within the msd locus,
wherein the msr locus and the msd locus form a RT binding region; and
(b) culturing the host cell or transformed progeny of the host cell under conditions sufficient for expressing from the one or more vectors the heterologous nucleic acid molecule comprising a retron transcript and a gRNA molecule to induce one or more sequence modifications in one or more target nucleic acids of interest at the one or more target loci within the genome.

### Claim 2 (depends on 1)

The method of claim 1, wherein the coding region comprises a nucleic acid molecule comprising:
a nucleic acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to any one of SEQ ID NO: 7 (CGCCAGTA), 4, 5, 6, 8, 14, 15, 16, 17, or 18, upstream of the donor DNA sequence; and
a nucleic acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to any one of SEQ ID NO: 12 (TAATGG), 9, 10, 11, 13, 19, 20, 21, 22, or 23, downstream of the donor DNA sequence.

### Claim 3 (depends on 2)

The method of claim 2, wherein the coding region comprises a nucleic acid molecule comprising:
a nucleic acid sequence of SEQ ID NO: 7 (CGCCAGTA) upstream of the donor DNA sequence; and a nucleic acid sequence of SEQ ID NO: 12 (TAATGG) downstream of the donor DNA sequence;
a nucleic acid sequence of SEQ ID NO: 4 upstream of the donor DNA sequence; and a nucleic acid sequence of SEQ ID NO: 9 downstream of the donor DNA sequence;
a nucleic acid sequence of SEQ ID NO: 4 upstream of the donor DNA sequence; and a nucleic acid sequence of SEQ ID NO: 10 downstream of the donor DNA sequence;
a nucleic acid sequence of SEQ ID NO: 4 upstream of the donor DNA sequence; and a nucleic acid sequence of SEQ ID NO: 11 downstream of the donor DNA sequence;
a nucleic acid sequence of SEQ ID NO: 4 upstream of the donor DNA sequence; and a nucleic acid sequence of SEQ ID NO: 12 downstream of the donor DNA sequence;
a nucleic acid sequence of SEQ ID NO: 4 upstream of the donor DNA sequence; and a nucleic acid sequence of SEQ ID NO: 13 downstream of the donor DNA sequence;
a nucleic acid sequence of SEQ ID NO: 5 upstream of the donor DNA sequence; and a nucleic acid sequence of SEQ ID NO: 9 downstream of the donor DNA sequence;
a nucleic acid sequence of SEQ ID NO: 5 upstream of the donor DNA sequence; and a nucleic acid sequence of SEQ ID NO: 10 downstream of the donor DNA sequence;
a nucleic acid sequence of SEQ ID NO: 5 upstream of the donor DNA sequence; and a nucleic acid sequence of SEQ ID NO: 11 downstream of the donor DNA sequence;
a nucleic acid sequence of SEQ ID NO: 5 upstream of the donor DNA sequence; and a nucleic acid sequence of SEQ ID NO: 12 downstream of the donor DNA sequence;
a nucleic acid sequence of SEQ ID NO: 5 upstream of the donor DNA sequence; and a nucleic acid sequence of SEQ ID NO: 13 downstream of the donor DNA sequence;
a nucleic acid sequence of SEQ ID NO: 6 upstream of the donor DNA sequence; and a nucleic acid sequence of SEQ ID NO: 9 downstream of the donor DNA sequence;
a nucleic acid sequence of SEQ ID NO: 6 upstream of the donor DNA sequence; and a nucleic acid sequence of SEQ ID NO: 10 downstream of the donor DNA sequence;
a nucleic acid sequence of SEQ ID NO: 6 upstream of the donor DNA sequence; and a nucleic acid sequence of SEQ ID NO: 11 downstream of the donor DNA sequence;
a nucleic acid sequence of SEQ ID NO: 6 upstream of the donor DNA sequence; and a nucleic acid sequence of SEQ ID NO: 12 downstream of the donor DNA sequence;
a nucleic acid sequence of SEQ ID NO: 6 upstream of the donor DNA sequence; and a nucleic acid sequence of SEQ ID NO: 13 downstream of the donor DNA sequence;
a nucleic acid sequence of SEQ ID NO: 7 upstream of the donor DNA sequence; and a nucleic acid sequence of SEQ ID NO: 9 downstream of the donor DNA sequence;
a nucleic acid sequence of SEQ ID NO: 7 upstream of the donor DNA sequence; and a nucleic acid sequence of SEQ ID NO: 10 downstream of the donor DNA sequence;
a nucleic acid sequence of SEQ ID NO: 7 upstream of the donor DNA sequence; and a nucleic acid sequence of SEQ ID NO: 11 downstream of the donor DNA sequence;
a nucleic acid sequence of SEQ ID NO: 7 upstream of the donor DNA sequence; and a nucleic acid sequence of SEQ ID NO: 13 downstream of the donor DNA sequence;
a nucleic acid sequence of SEQ ID NO: 8 upstream of the donor DNA sequence; and a nucleic acid sequence of SEQ ID NO: 9 downstream of the donor DNA sequence;
a nucleic acid sequence of SEQ ID NO: 8 upstream of the donor DNA sequence; and a nucleic acid sequence of SEQ ID NO: 10 downstream of the donor DNA sequence;
a nucleic acid sequence of SEQ ID NO: 8 upstream of the donor DNA sequence; and a nucleic acid sequence of SEQ ID NO: 11 downstream of the donor DNA sequence;
a nucleic acid sequence of SEQ ID NO: 8 upstream of the donor DNA sequence; and a nucleic acid sequence of SEQ ID NO: 12 downstream of the donor DNA sequence; or
a nucleic acid sequence of SEQ ID NO: 8 upstream of the donor DNA sequence; and a nucleic acid sequence of SEQ ID NO: 13 downstream of the donor DNA sequence.

### Claim 4 (depends on 1)

The method of claim 1, wherein the msd locus comprises a deletion of at least 1 nucleotide as compared to SEQ ID NO: 1, or 2.

### Claim 5 (depends on 4)

The method of claim 4, wherein the msd locus comprises a deletion of about 1 to 150, about 1 to about 125, about 1 to about 100, about 1 to about 90, about 1 to about 80, about 1 to about 70, about 1 to about 60, about 1 to about 50, about 1 to about 40, about 1 to about 30, about 1 to about 20, or about 1 to about 10 nucleotides as compared to SEQ ID NO: 1, or 2.

### Claim 6 (depends on 2)

The method of claim 2, wherein the msd locus upstream (to the 5′ of) of the donor DNA sequence comprises a nucleic acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to any one of SEQ ID NO: 4, 5, 6, 7, 8, 14, 15, 16, 17, or 18.

### Claim 7 (depends on 4)

The method of claim 4, wherein the msd locus upstream (to the 5′ of) of the donor DNA sequence comprises a nucleic acid sequence of any one of SEQ ID NO: 4, 5, 6, 7, 8, 14, 15, 16, 17, or 18.

### Claim 8 (depends on 2)

The method of claim 2, wherein the msd locus downstream (to the 3′ of) of the donor DNA sequence comprises a nucleic acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to any one of SEQ ID NO: 9, 10, 11, 12, 13, 19, 20, 21, 22, or 23.

### Claim 9 (depends on 8)

The method of claim 8, wherein the msd locus downstream (to the 3′ of) of the donor DNA sequence comprises a nucleic acid sequence of any one of SEQ ID NO: 9, 10, 11, 12, 13, 19, 20, 21, 22, or 23.

### Claim 10 (depends on 2)

The method of claim 2, wherein the coding region comprises a nucleic acid molecule comprising:
a nucleic acid sequence of any one of SEQ ID NO: 4, 5, 6, 7, 8, 14, 15, 16, 17, or 18, upstream of the donor DNA sequence; and
a nucleic acid sequence of any one of SEQ ID NO: 9, 10, 11, 12, 13, 19, 20, 21, 22, or 23, downstream of the donor DNA sequence.

### Claim 11 (depends on 1)

The method of claim 1, wherein the coding region comprises a nucleic acid molecule having a formula of 5′-M1-X1-M2-3′, wherein M1 is a fragment of the msr locus and the msd locus, X1 is the donor DNA sequence coding region; and M2 is a fragment of the msr locus and the msd locus.

### Claim 12 (depends on 11)

The method of claim 11, wherein the nucleic acid molecule comprises:
an M1 having a nucleic acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to any one of SEQ ID NO: 24, 25, 26, 27, 28, 29, 30, 31, 32, or 33; and
an M2 having a nucleic acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to any one of SEQ ID NO: 34, 35, 36, 37, 38, 39, 40, 41, 42, or 43.

### Claim 13 (depends on 12)

The method of claim 12, wherein the nucleic acid molecule comprises
an M1 having a nucleic acid sequence of SEQ ID NO: 24; and an M2 having a nucleic acid sequence of SEQ ID NO: 34;
an M1 having a nucleic acid sequence of SEQ ID NO: 24; and an M2 having a nucleic acid sequence of SEQ ID NO: 35;
an M1 having a nucleic acid sequence of SEQ ID NO: 24; and an M2 having a nucleic acid sequence of SEQ ID NO: 36;
an M1 having a nucleic acid sequence of SEQ ID NO: 24; and an M2 having a nucleic acid sequence of SEQ ID NO: 37;
an M1 having a nucleic acid sequence of SEQ ID NO: 24; and an M2 having a nucleic acid sequence of SEQ ID NO: 38;
an M1 having a nucleic acid sequence of SEQ ID NO: 24; and an M2 having a nucleic acid sequence of SEQ ID NO: 39;
an M1 having a nucleic acid sequence of SEQ ID NO: 24; and an M2 having a nucleic acid sequence of SEQ ID NO: 40;
an M1 having a nucleic acid sequence of SEQ ID NO: 24; and an M2 having a nucleic acid sequence of SEQ ID NO: 41;
an M1 having a nucleic acid sequence of SEQ ID NO: 24; and an M2 having a nucleic acid sequence of SEQ ID NO: 42;
an M1 having a nucleic acid sequence of SEQ ID NO: 24; and an M2 having a nucleic acid sequence of SEQ ID NO: 43;
an M1 having a nucleic acid sequence of SEQ ID NO: 25; and an M2 having a nucleic acid sequence of SEQ ID NO: 34;
an M1 having a nucleic acid sequence of SEQ ID NO: 25; and an M2 having a nucleic acid sequence of SEQ ID NO: 35;
an M1 having a nucleic acid sequence of SEQ ID NO: 25; and an M2 having a nucleic acid sequence of SEQ ID NO: 36;
an M1 having a nucleic acid sequence of SEQ ID NO: 25; and an M2 having a nucleic acid sequence of SEQ ID NO: 37;
an M1 having a nucleic acid sequence of SEQ ID NO: 25; and an M2 having a nucleic acid sequence of SEQ ID NO: 38;
an M1 having a nucleic acid sequence of SEQ ID NO: 25; and an M2 having a nucleic acid sequence of SEQ ID NO: 39;
an M1 having a nucleic acid sequence of SEQ ID NO: 25; and an M2 having a nucleic acid sequence of SEQ ID NO: 40;
an M1 having a nucleic acid sequence of SEQ ID NO: 25; and an M2 having a nucleic acid sequence of SEQ ID NO: 41;
an M1 having a nucleic acid sequence of SEQ ID NO: 25; and an M2 having a nucleic acid sequence of SEQ ID NO: 42;
an M1 having a nucleic acid sequence of SEQ ID NO: 25; and an M2 having a nucleic acid sequence of SEQ ID NO: 43;
an M1 having a nucleic acid sequence of SEQ ID NO: 26; and an M2 having a nucleic acid sequence of SEQ ID NO: 34;
an M1 having a nucleic acid sequence of SEQ ID NO: 26; and an M2 having a nucleic acid sequence of SEQ ID NO: 35;
an M1 having a nucleic acid sequence of SEQ ID NO: 26; and an M2 having a nucleic acid sequence of SEQ ID NO: 36;
an M1 having a nucleic acid sequence of SEQ ID NO: 26; and an M2 having a nucleic acid sequence of SEQ ID NO: 37;
an M1 having a nucleic acid sequence of SEQ ID NO: 26; and an M2 having a nucleic acid sequence of SEQ ID NO: 38;
an M1 having a nucleic acid sequence of SEQ ID NO: 26; and an M2 having a nucleic acid sequence of SEQ ID NO: 39;
an M1 having a nucleic acid sequence of SEQ ID NO: 26; and an M2 having a nucleic acid sequence of SEQ ID NO: 40;
an M1 having a nucleic acid sequence of SEQ ID NO: 26; and an M2 having a nucleic acid sequence of SEQ ID NO: 41;
an M1 having a nucleic acid sequence of SEQ ID NO: 26; and an M2 having a nucleic acid sequence of SEQ ID NO: 42;
an M1 having a nucleic acid sequence of SEQ ID NO: 26; and an M2 having a nucleic acid sequence of SEQ ID NO: 43;
an M1 having a nucleic acid sequence of SEQ ID NO: 27; and an M2 having a nucleic acid sequence of SEQ ID NO: 34;
an M1 having a nucleic acid sequence of SEQ ID NO: 27; and an M2 having a nucleic acid sequence of SEQ ID NO: 35;
an M1 having a nucleic acid sequence of SEQ ID NO: 27; and an M2 having a nucleic acid sequence of SEQ ID NO: 36;
an M1 having a nucleic acid sequence of SEQ ID NO: 27; and an M2 having a nucleic acid sequence of SEQ ID NO: 37;
an M1 having a nucleic acid sequence of SEQ ID NO: 27; and an M2 having a nucleic acid sequence of SEQ ID NO: 38;
an M1 having a nucleic acid sequence of SEQ ID NO: 27; and an M2 having a nucleic acid sequence of SEQ ID NO: 39;
an M1 having a nucleic acid sequence of SEQ ID NO: 27; and an M2 having a nucleic acid sequence of SEQ ID NO: 40;
an M1 having a nucleic acid sequence of SEQ ID NO: 27; and an M2 having a nucleic acid sequence of SEQ ID NO: 41;
an M1 having a nucleic acid sequence of SEQ ID NO: 27; and an M2 having a nucleic acid sequence of SEQ ID NO: 42;
an M1 having a nucleic acid sequence of SEQ ID NO: 27; and an M2 having a nucleic acid sequence of SEQ ID NO: 43;
an M1 having a nucleic acid sequence of SEQ ID NO: 28; and an M2 having a nucleic acid sequence of SEQ ID NO: 34;
an M1 having a nucleic acid sequence of SEQ ID NO: 28; and an M2 having a nucleic acid sequence of SEQ ID NO: 35;
an M1 having a nucleic acid sequence of SEQ ID NO: 28; and an M2 having a nucleic acid sequence of SEQ ID NO: 36;
an M1 having a nucleic acid sequence of SEQ ID NO: 28; and an M2 having a nucleic acid sequence of SEQ ID NO: 37;
an M1 having a nucleic acid sequence of SEQ ID NO: 28; and an M2 having a nucleic acid sequence of SEQ ID NO: 38;
an M1 having a nucleic acid sequence of SEQ ID NO: 28; and an M2 having a nucleic acid sequence of SEQ ID NO: 39;
an M1 having a nucleic acid sequence of SEQ ID NO: 28; and an M2 having a nucleic acid sequence of SEQ ID NO: 40;
an M1 having a nucleic acid sequence of SEQ ID NO: 28; and an M2 having a nucleic acid sequence of SEQ ID NO: 41;
an M1 having a nucleic acid sequence of SEQ ID NO: 28; and an M2 having a nucleic acid sequence of SEQ ID NO: 42;
an M1 having a nucleic acid sequence of SEQ ID NO: 28; and an M2 having a nucleic acid sequence of SEQ ID NO: 43;
an M1 having a nucleic acid sequence of SEQ ID NO: 29; and an M2 having a nucleic acid sequence of SEQ ID NO: 34;
an M1 having a nucleic acid sequence of SEQ ID NO: 29; and an M2 having a nucleic acid sequence of SEQ ID NO: 35;
an M1 having a nucleic acid sequence of SEQ ID NO: 29; and an M2 having a nucleic acid sequence of SEQ ID NO: 36;
an M1 having a nucleic acid sequence of SEQ ID NO: 29; and an M2 having a nucleic acid sequence of SEQ ID NO: 37;
an M1 having a nucleic acid sequence of SEQ ID NO: 29; and an M2 having a nucleic acid sequence of SEQ ID NO: 38;
an M1 having a nucleic acid sequence of SEQ ID NO: 29; and an M2 having a nucleic acid sequence of SEQ ID NO: 39;
an M1 having a nucleic acid sequence of SEQ ID NO: 29; and an M2 having a nucleic acid sequence of SEQ ID NO: 40;
an M1 having a nucleic acid sequence of SEQ ID NO: 29; and an M2 having a nucleic acid sequence of SEQ ID NO: 41;
an M1 having a nucleic acid sequence of SEQ ID NO: 29; and an M2 having a nucleic acid sequence of SEQ ID NO: 42;
an M1 having a nucleic acid sequence of SEQ ID NO: 29; and an M2 having a nucleic acid sequence of SEQ ID NO: 43;
an M1 having a nucleic acid sequence of SEQ ID NO: 30; and an M2 having a nucleic acid sequence of SEQ ID NO: 34;
an M1 having a nucleic acid sequence of SEQ ID NO: 30; and an M2 having a nucleic acid sequence of SEQ ID NO: 35;
an M1 having a nucleic acid sequence of SEQ ID NO: 30; and an M2 having a nucleic acid sequence of SEQ ID NO: 36;
an M1 having a nucleic acid sequence of SEQ ID NO: 30; and an M2 having a nucleic acid sequence of SEQ ID NO: 37;
an M1 having a nucleic acid sequence of SEQ ID NO: 30; and an M2 having a nucleic acid sequence of SEQ ID NO: 38;
an M1 having a nucleic acid sequence of SEQ ID NO: 30; and an M2 having a nucleic acid sequence of SEQ ID NO: 39;
an M1 having a nucleic acid sequence of SEQ ID NO: 30; and an M2 having a nucleic acid sequence of SEQ ID NO: 40;
an M1 having a nucleic acid sequence of SEQ ID NO: 30; and an M2 having a nucleic acid sequence of SEQ ID NO: 41;
an M1 having a nucleic acid sequence of SEQ ID NO: 30; and an M2 having a nucleic acid sequence of SEQ ID NO: 42;
an M1 having a nucleic acid sequence of SEQ ID NO: 30; and an M2 having a nucleic acid sequence of SEQ ID NO: 43;
an M1 having a nucleic acid sequence of SEQ ID NO: 31; and an M2 having a nucleic acid sequence of SEQ ID NO: 34;
an M1 having a nucleic acid sequence of SEQ ID NO: 31; and an M2 having a nucleic acid sequence of SEQ ID NO: 35;
an M1 having a nucleic acid sequence of SEQ ID NO: 31; and an M2 having a nucleic acid sequence of SEQ ID NO: 36;
an M1 having a nucleic acid sequence of SEQ ID NO: 31; and an M2 having a nucleic acid sequence of SEQ ID NO: 37;
an M1 having a nucleic acid sequence of SEQ ID NO: 31; and an M2 having a nucleic acid sequence of SEQ ID NO: 38;
an M1 having a nucleic acid sequence of SEQ ID NO: 31; and an M2 having a nucleic acid sequence of SEQ ID NO: 39;
an M1 having a nucleic acid sequence of SEQ ID NO: 31; and an M2 having a nucleic acid sequence of SEQ ID NO: 40;
an M1 having a nucleic acid sequence of SEQ ID NO: 31; and an M2 having a nucleic acid sequence of SEQ ID NO: 41;
an M1 having a nucleic acid sequence of SEQ ID NO: 31; and an M2 having a nucleic acid sequence of SEQ ID NO: 42;
an M1 having a nucleic acid sequence of SEQ ID NO: 31; and an M2 having a nucleic acid sequence of SEQ ID NO: 43;
an M1 having a nucleic acid sequence of SEQ ID NO: 32; and an M2 having a nucleic acid sequence of SEQ ID NO: 34;
an M1 having a nucleic acid sequence of SEQ ID NO: 32; and an M2 having a nucleic acid sequence of SEQ ID NO: 35;
an M1 having a nucleic acid sequence of SEQ ID NO: 32; and an M2 having a nucleic acid sequence of SEQ ID NO: 36;
an M1 having a nucleic acid sequence of SEQ ID NO: 32; and an M2 having a nucleic acid sequence of SEQ ID NO: 37;
an M1 having a nucleic acid sequence of SEQ ID NO: 32; and an M2 having a nucleic acid sequence of SEQ ID NO: 38;
an M1 having a nucleic acid sequence of SEQ ID NO: 32; and an M2 having a nucleic acid sequence of SEQ ID NO: 39;
an M1 having a nucleic acid sequence of SEQ ID NO: 32; and an M2 having a nucleic acid sequence of SEQ ID NO: 40;
an M1 having a nucleic acid sequence of SEQ ID NO: 32; and an M2 having a nucleic acid sequence of SEQ ID NO: 41;
an M1 having a nucleic acid sequence of SEQ ID NO: 32; and an M2 having a nucleic acid sequence of SEQ ID NO: 42;
an M1 having a nucleic acid sequence of SEQ ID NO: 32; and an M2 having a nucleic acid sequence of SEQ ID NO: 43;
an M1 having a nucleic acid sequence of SEQ ID NO: or 33; and an M2 having a nucleic acid sequence of SEQ ID NO: 34;
an M1 having a nucleic acid sequence of SEQ ID NO: or 33; and an M2 having a nucleic acid sequence of SEQ ID NO: 35;
an M1 having a nucleic acid sequence of SEQ ID NO: or 33; and an M2 having a nucleic acid sequence of SEQ ID NO: 36;
an M1 having a nucleic acid sequence of SEQ ID NO: or 33; and an M2 having a nucleic acid sequence of SEQ ID NO: 37;
an M1 having a nucleic acid sequence of SEQ ID NO: or 33; and an M2 having a nucleic acid sequence of SEQ ID NO: 38;
an M1 having a nucleic acid sequence of SEQ ID NO: or 33; and an M2 having a nucleic acid sequence of SEQ ID NO: 39;
an M1 having a nucleic acid sequence of SEQ ID NO: or 33; and an M2 having a nucleic acid sequence of SEQ ID NO: 40;
an M1 having a nucleic acid sequence of SEQ ID NO: or 33; and an M2 having a nucleic acid sequence of SEQ ID NO: 41;
an M1 having a nucleic acid sequence of SEQ ID NO: or 33; and an M2 having a nucleic acid sequence of SEQ ID NO: 42; or
an M1 having a nucleic acid sequence of SEQ ID NO: or 33; and an M2 having a nucleic acid sequence of SEQ ID NO: 43.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The method of any one of claims 1-13, wherein the donor DNA sequence is a target strand donor DNA sequence.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The method of any one of claims 1-14, wherein the host cell expresses a nuclease and a RT protein.

### Claim 16 (depends on 15)

The method claim 15, wherein the nuclease and RT are:
not expressed as a fusion molecule; or
expressed as a fusion protein.

### Claim 17 (depends on 15, 16)

The method of claims 15-16, wherein the nuclease is linked to the RT with a linker.

### Claim 18 (depends on 17)

The method of claim 17, wherein the linker is a peptide linker.

### Claim 19 (depends on 15, 16, 17, 18)

The method of any one of claims 15-18, wherein the C-terminus of the nuclease is linked to the N-terminus of the RT, or the N-terminus of the nuclease is linked to the C-terminus of the RT.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method of any one of claims 1-19, wherein the host cell expresses a RT and a single-stranded annealing protein (SSAP).

### Claim 21 (depends on 15, 16, 17, 18, 19, 20)

The method of any one of claims 15-20, wherein the nuclease is a Cas nuclease, such as a catalytically active nuclease, a nickase Cas nuclease, a catalytically inactive Cas nuclease, a Cas9 nuclease, nickase Cas9 nuclease, a catalytically inactive Cas9 nuclease, Cas9D10A nickase, Cas9H840A nickase, or a Cas having D10A and H840A mutations.

### Claim 22 (depends on 15, 16, 17, 18, 19, 20, 21)

The method of any one of claims 15-21, wherein the RT is a fusion protein comprising a polypeptide having the formula of: of (N1)q-C1-L1-(N2)qq-R1-(N3)qqq, wherein C1 is a nuclease, L1 is a peptide linker, R1 is a RT protein, and N1 and N2 are each independently, a NLS sequence, and wherein q, qq, or qqq, are each independently, 0, 1, 2, or 3.

### Claim 23 (depends on 22)

The method of claim 22, wherein the polypeptide has the formula of:
wherein:
each N1, N1A, N2, N3, or N3A is, independently, a NLS sequence;
each L1, L2, or L3 is independently, a linker amino acid sequence; and
wherein each NLS sequence is identical or different.

### Claim 24 (depends on 22, 23)

The method of any one of claims 22-23, wherein N1, N1A, N2, N3, or N3A, each independently comprise a SV40 NLS sequence, a cMyc NLS sequence, or a Nuceloplasmin NLS sequence.

### Claim 25 (depends on 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The method of any one of claims 15-24, wherein R1 comprises a RT sequence Ec86, Ec48, Ec73, Ec107, or Sa163.

### Claim 26 (depends on 22, 23, 24, 25)

The method of any one of claims 22-25, wherein the polypeptide comprises an amino acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to any one of SEQ ID NO: 70, 71, 72, 73, or 74.

### Claim 27 (depends on 26)

The method of claim 26, wherein the polypeptide comprises an amino acid sequence of any one of SEQ ID NO: 70, 71, 72, 73, or 74.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

The method of any one of claims 1-27, wherein the retron transcript and the gRNA are not linked together; or wherein the retron transcript and the gRNA are linked together, such as part of the same contiguous transcript, or not part of the same contiguous transcript.

### Claim 29 (depends on 28)

The method of claim 28, wherein the retron and gRNA are covalently linked together.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The method of any one of claims 1-29, wherein the retron transcript and the gRNA comprises a structured motif at a 5′ or a 3′ end of the retron transcript and the gRNA, such as evoPreQ, tevopreQ mpKnot, or exoribonuclease-resistant RNA motif.

### Claim 31 (depends on 30)

The method of claim 30, wherein the structured motif comprises a nucleic acid sequence selected from any one of SEQ ID NO: 75, 76, 77, 78, 79, 80, 81, or 82.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The method of any one of claims 1-31, wherein the retron transcript linked to the gRNA molecule comprises a formula A1-Rt-L1n-gRNA-A2, wherein:
(a) A1 is the structured motif, or is absent;
Rt is the retron transcript;
L1n is a nucleotide linker from about 5 to about 40, about 8 to about 35, about 9, or about 33 basepairs, or is absent; and
A2 is the structured motif, or is absent;
(b) A1 is the structured motif;
Rt is the retron transcript;
L1n is a nucleotide linker from about 5 to about 40, about 8 to about 35, about 9, or about 33 basepairs; and
A2 is absent; or
(c) A1 is absent;
Rt is the retron transcript;
L1 is a nucleotide linker from about 5 to about 40, about 8 to about 35, about 9, or about 33 base pairs; and
A2 is the structured motif.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

A method of treating a disease or condition by modifying one or more target nucleic acids of interest at one or more target loci within a genome of a host cell, such as a mammalian cells, the method comprising the method of any one of claims 1-32.

### Claim 34 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

A method for modifying one or more target nucleic acids of interest at one or more target loci within a genome of a host cell, such as a mammalian cells, the method comprising the method of any one of claims 1-32.

### Claim 35

A retron-guide RNA (gRNA) cassette comprising:
a retron comprising:
a first inverted repeat sequence coding region;
an msr locus and an msd locus;
a donor DNA sequence within the msd locus; and
a second inverted repeat sequence coding region; and
optionally a gRNA coding region,
wherein the msr locus and the msd locus comprise the nucleic acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to any one of SEQ ID NO: 1, or 2.

### Claim 36 (depends on 35)

The cassette of claim 35, wherein the retron comprises a nucleic acid molecule comprising:
a nucleic acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to any one of SEQ ID NO: 7, 4, 5, 6, 8, 14, 15, 16, 17, or 18, upstream of the donor DNA sequence; and
a nucleic acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to any one of SEQ ID NO: 12, 9, 10, 11, 13, 19, 20, 21, 22, or 23, downstream of the donor DNA sequence.

### Claim 37 (depends on 36)

The cassette of claim 36, wherein the retron comprises a nucleic acid molecule comprising:
a nucleic acid sequence of SEQ ID NO: 7 upstream of the donor DNA sequence; and a nucleic acid sequence of SEQ ID NO: 12 downstream of the donor DNA sequence;
a nucleic acid sequence of SEQ ID NO: 4 upstream of the donor DNA sequence; and a nucleic acid sequence of SEQ ID NO: 9 downstream of the donor DNA sequence;
a nucleic acid sequence of SEQ ID NO: 4 upstream of the donor DNA sequence; and a nucleic acid sequence of SEQ ID NO: 10 downstream of the donor DNA sequence;
a nucleic acid sequence of SEQ ID NO: 4 upstream of the donor DNA sequence; and a nucleic acid sequence of SEQ ID NO: 11 downstream of the donor DNA sequence;
a nucleic acid sequence of SEQ ID NO: 4 upstream of the donor DNA sequence; and a nucleic acid sequence of SEQ ID NO: 12 downstream of the donor DNA sequence;
a nucleic acid sequence of SEQ ID NO: 4 upstream of the donor DNA sequence; and a nucleic acid sequence of SEQ ID NO: 13 downstream of the donor DNA sequence;
a nucleic acid sequence of SEQ ID NO: 5 upstream of the donor DNA sequence; and a nucleic acid sequence of SEQ ID NO: 9 downstream of the donor DNA sequence;
a nucleic acid sequence of SEQ ID NO: 5 upstream of the donor DNA sequence; and a nucleic acid sequence of SEQ ID NO: 10 downstream of the donor DNA sequence;
a nucleic acid sequence of SEQ ID NO: 5 upstream of the donor DNA sequence; and a nucleic acid sequence of SEQ ID NO: 11 downstream of the donor DNA sequence;
a nucleic acid sequence of SEQ ID NO: 5 upstream of the donor DNA sequence; and a nucleic acid sequence of SEQ ID NO: 12 downstream of the donor DNA sequence;
a nucleic acid sequence of SEQ ID NO: 5 upstream of the donor DNA sequence; and a nucleic acid sequence of SEQ ID NO: 13 downstream of the donor DNA sequence;
a nucleic acid sequence of SEQ ID NO: 6 upstream of the donor DNA sequence; and a nucleic acid sequence of SEQ ID NO: 9 downstream of the donor DNA sequence;
a nucleic acid sequence of SEQ ID NO: 6 upstream of the donor DNA sequence; and a nucleic acid sequence of SEQ ID NO: 10 downstream of the donor DNA sequence;
a nucleic acid sequence of SEQ ID NO: 6 upstream of the donor DNA sequence; and a nucleic acid sequence of SEQ ID NO: 11 downstream of the donor DNA sequence;
a nucleic acid sequence of SEQ ID NO: 6 upstream of the donor DNA sequence; and a nucleic acid sequence of SEQ ID NO: 12 downstream of the donor DNA sequence;
a nucleic acid sequence of SEQ ID NO: 6 upstream of the donor DNA sequence; and a nucleic acid sequence of SEQ ID NO: 13 downstream of the donor DNA sequence;
a nucleic acid sequence of SEQ ID NO: 7 upstream of the donor DNA sequence; and a nucleic acid sequence of SEQ ID NO: 9 downstream of the donor DNA sequence;
a nucleic acid sequence of SEQ ID NO: 7 upstream of the donor DNA sequence; and a nucleic acid sequence of SEQ ID NO: 10 downstream of the donor DNA sequence;
a nucleic acid sequence of SEQ ID NO: 7 upstream of the donor DNA sequence; and a nucleic acid sequence of SEQ ID NO: 11 downstream of the donor DNA sequence;
a nucleic acid sequence of SEQ ID NO: 7 upstream of the donor DNA sequence; and a nucleic acid sequence of SEQ ID NO: 13 downstream of the donor DNA sequence;
a nucleic acid sequence of SEQ ID NO: 8 upstream of the donor DNA sequence; and a nucleic acid sequence of SEQ ID NO: 9 downstream of the donor DNA sequence;
a nucleic acid sequence of SEQ ID NO: 8 upstream of the donor DNA sequence; and a nucleic acid sequence of SEQ ID NO: 10 downstream of the donor DNA sequence;
a nucleic acid sequence of SEQ ID NO: 8 upstream of the donor DNA sequence; and a nucleic acid sequence of SEQ ID NO: 11 downstream of the donor DNA sequence;
a nucleic acid sequence of SEQ ID NO: 8 upstream of the donor DNA sequence; and a nucleic acid sequence of SEQ ID NO: 12 downstream of the donor DNA sequence; or
a nucleic acid sequence of SEQ ID NO: 8 upstream of the donor DNA sequence; and a nucleic acid sequence of SEQ ID NO: 13 downstream of the donor DNA sequence.

### Claim 38 (depends on 35)

The cassette of claim 35, wherein the msd locus comprises a deletion of at least 1 nucleotide as compared to SEQ ID NO: 1, or 2.

### Claim 39 (depends on 38)

The cassette of claim 38, wherein the msd locus comprises a deletion of about 1 to 150, about 1 to about 125, about 1 to about 100, about 1 to about 90, about 1 to about 80, about 1 to about 70, about 1 to about 60, about 1 to about 50, about 1 to about 40, about 1 to about 30, about 1 to about 20, or about 1 to about 10 nucleotides as compared to SEQ ID NO: 1, or 2.

### Claim 40 (depends on 36)

The cassette of claim 36, wherein the msd locus upstream (to the 5′ of) of the donor DNA sequence coding region comprises a nucleic acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to any one of SEQ ID NO: 4, 5, 6, 7, 8, 14, 15, 16, 17, or 18.

### Claim 41 (depends on 40)

The cassette of claim 40, wherein the msd locus upstream (to the 5′ of) of the donor DNA sequence coding region comprises a nucleic acid sequence of any one of SEQ ID NO: 4, 5, 6, 7, 8, 14, 15, 16, 17, or 18.

### Claim 42 (depends on 36)

The cassette of claim 36, wherein the msd locus downstream (to the 3′ of) of the donor DNA sequence coding region comprises a nucleic acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to any one of SEQ ID NO: 9, 10, 11, 12, 13, 19, 20, 21, 22, or 23.

### Claim 43 (depends on 42)

The cassette of claim 42, wherein the msd locus downstream (to the 3′ of) of the donor DNA sequence coding region comprises a nucleic acid sequence of any one of SEQ ID NO: 9, 10, 11, 12, 13, 19, 20, 21, 22, or 23.

### Claim 44 (depends on 36)

The cassette of claim 36, wherein the retron comprises a nucleic acid molecule comprising:
a nucleic acid sequence of any one of SEQ ID NO: 4, 5, 6, 7, 8, 14, 15, 16, 17, or 18, upstream of the donor DNA sequence coding region coding region; and
a nucleic acid sequence of any one of SEQ ID NO: 9, 10, 11, 12, 13, 19, 20, 21, 22, or 23, downstream of the donor DNA sequence.

### Claim 45 (depends on 35)

The cassette of claim 35, wherein the retron comprises a nucleic acid molecule having a formula of 5′-M1-X1-M2-3′, wherein M1 is a fragment of the msr locus and the msd locus, X1 is the donor DNA sequence; and M2 is a fragment of the msd locus and the msr locus.

### Claim 46 (depends on 45)

The cassette of claim 45, wherein the nucleic acid molecule comprises:
an M1 having a nucleic acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to any one of SEQ ID NO: 24, 25, 26, 27, 28, 29, 30, 31, 32, or 33; and
an M2 having a nucleic acid sequence having at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to any one of SEQ ID NO: 34, 35, 36, 37, 38, 39, 40, 41, 42, or 43.

### Claim 47 (depends on 46)

The cassette of claim 46, wherein the nucleic acid molecule comprises
an M1 having a nucleic acid sequence of SEQ ID NO: 24; and an M2 having a nucleic acid sequence of SEQ ID NO: 34;
an M1 having a nucleic acid sequence of SEQ ID NO: 24; and an M2 having a nucleic acid sequence of SEQ ID NO: 35;
an M1 having a nucleic acid sequence of SEQ ID NO: 24; and an M2 having a nucleic acid sequence of SEQ ID NO: 36;
an M1 having a nucleic acid sequence of SEQ ID NO: 24; and an M2 having a nucleic acid sequence of SEQ ID NO: 37;
an M1 having a nucleic acid sequence of SEQ ID NO: 24; and an M2 having a nucleic acid sequence of SEQ ID NO: 38;
an M1 having a nucleic acid sequence of SEQ ID NO: 24; and an M2 having a nucleic acid sequence of SEQ ID NO: 39;
an M1 having a nucleic acid sequence of SEQ ID NO: 24; and an M2 having a nucleic acid sequence of SEQ ID NO: 40;
an M1 having a nucleic acid sequence of SEQ ID NO: 24; and an M2 having a nucleic acid sequence of SEQ ID NO: 41;
an M1 having a nucleic acid sequence of SEQ ID NO: 24; and an M2 having a nucleic acid sequence of SEQ ID NO: 42;
an M1 having a nucleic acid sequence of SEQ ID NO: 24; and an M2 having a nucleic acid sequence of SEQ ID NO: 43;
an M1 having a nucleic acid sequence of SEQ ID NO: 25; and an M2 having a nucleic acid sequence of SEQ ID NO: 34;
an M1 having a nucleic acid sequence of SEQ ID NO: 25; and an M2 having a nucleic acid sequence of SEQ ID NO: 35;
an M1 having a nucleic acid sequence of SEQ ID NO: 25; and an M2 having a nucleic acid sequence of SEQ ID NO: 36;
an M1 having a nucleic acid sequence of SEQ ID NO: 25; and an M2 having a nucleic acid sequence of SEQ ID NO: 37;
an M1 having a nucleic acid sequence of SEQ ID NO: 25; and an M2 having a nucleic acid sequence of SEQ ID NO: 38;
an M1 having a nucleic acid sequence of SEQ ID NO: 25; and an M2 having a nucleic acid sequence of SEQ ID NO: 39;
an M1 having a nucleic acid sequence of SEQ ID NO: 25; and an M2 having a nucleic acid sequence of SEQ ID NO: 40;
an M1 having a nucleic acid sequence of SEQ ID NO: 25; and an M2 having a nucleic acid sequence of SEQ ID NO: 41;
an M1 having a nucleic acid sequence of SEQ ID NO: 25; and an M2 having a nucleic acid sequence of SEQ ID NO: 42;
an M1 having a nucleic acid sequence of SEQ ID NO: 25; and an M2 having a nucleic acid sequence of SEQ ID NO: 43;
an M1 having a nucleic acid sequence of SEQ ID NO: 26; and an M2 having a nucleic acid sequence of SEQ ID NO: 34;
an M1 having a nucleic acid sequence of SEQ ID NO: 26; and an M2 having a nucleic acid sequence of SEQ ID NO: 35;
an M1 having a nucleic acid sequence of SEQ ID NO: 26; and an M2 having a nucleic acid sequence of SEQ ID NO: 36;
an M1 having a nucleic acid sequence of SEQ ID NO: 26; and an M2 having a nucleic acid sequence of SEQ ID NO: 37;
an M1 having a nucleic acid sequence of SEQ ID NO: 26; and an M2 having a nucleic acid sequence of SEQ ID NO: 38;
an M1 having a nucleic acid sequence of SEQ ID NO: 26; and an M2 having a nucleic acid sequence of SEQ ID NO: 39;
an M1 having a nucleic acid sequence of SEQ ID NO: 26; and an M2 having a nucleic acid sequence of SEQ ID NO: 40;
an M1 having a nucleic acid sequence of SEQ ID NO: 26; and an M2 having a nucleic acid sequence of SEQ ID NO: 41;
an M1 having a nucleic acid sequence of SEQ ID NO: 26; and an M2 having a nucleic acid sequence of SEQ ID NO: 42;
an M1 having a nucleic acid sequence of SEQ ID NO: 26; and an M2 having a nucleic acid sequence of SEQ ID NO: 43;
an M1 having a nucleic acid sequence of SEQ ID NO: 27; and an M2 having a nucleic acid sequence of SEQ ID NO: 34;
an M1 having a nucleic acid sequence of SEQ ID NO: 27; and an M2 having a nucleic acid sequence of SEQ ID NO: 35;
an M1 having a nucleic acid sequence of SEQ ID NO: 27; and an M2 having a nucleic acid sequence of SEQ ID NO: 36;
an M1 having a nucleic acid sequence of SEQ ID NO: 27; and an M2 having a nucleic acid sequence of SEQ ID NO: 37;
an M1 having a nucleic acid sequence of SEQ ID NO: 27; and an M2 having a nucleic acid sequence of SEQ ID NO: 38;
an M1 having a nucleic acid sequence of SEQ ID NO: 27; and an M2 having a nucleic acid sequence of SEQ ID NO: 39;
an M1 having a nucleic acid sequence of SEQ ID NO: 27; and an M2 having a nucleic acid sequence of SEQ ID NO: 40;
an M1 having a nucleic acid sequence of SEQ ID NO: 27; and an M2 having a nucleic acid sequence of SEQ ID NO: 41;
an M1 having a nucleic acid sequence of SEQ ID NO: 27; and an M2 having a nucleic acid sequence of SEQ ID NO: 42;
an M1 having a nucleic acid sequence of SEQ ID NO: 27; and an M2 having a nucleic acid sequence of SEQ ID NO: 43;
an M1 having a nucleic acid sequence of SEQ ID NO: 28; and an M2 having a nucleic acid sequence of SEQ ID NO: 34;
an M1 having a nucleic acid sequence of SEQ ID NO: 28; and an M2 having a nucleic acid sequence of SEQ ID NO: 35;
an M1 having a nucleic acid sequence of SEQ ID NO: 28; and an M2 having a nucleic acid sequence of SEQ ID NO: 36;
an M1 having a nucleic acid sequence of SEQ ID NO: 28; and an M2 having a nucleic acid sequence of SEQ ID NO: 37;
an M1 having a nucleic acid sequence of SEQ ID NO: 28; and an M2 having a nucleic acid sequence of SEQ ID NO: 38;
an M1 having a nucleic acid sequence of SEQ ID NO: 28; and an M2 having a nucleic acid sequence of SEQ ID NO: 39;
an M1 having a nucleic acid sequence of SEQ ID NO: 28; and an M2 having a nucleic acid sequence of SEQ ID NO: 40;
an M1 having a nucleic acid sequence of SEQ ID NO: 28; and an M2 having a nucleic acid sequence of SEQ ID NO: 41;
an M1 having a nucleic acid sequence of SEQ ID NO: 28; and an M2 having a nucleic acid sequence of SEQ ID NO: 42;
an M1 having a nucleic acid sequence of SEQ ID NO: 28; and an M2 having a nucleic acid sequence of SEQ ID NO: 43;
an M1 having a nucleic acid sequence of SEQ ID NO: 29; and an M2 having a nucleic acid sequence of SEQ ID NO: 34;
an M1 having a nucleic acid sequence of SEQ ID NO: 29; and an M2 having a nucleic acid sequence of SEQ ID NO: 35;
an M1 having a nucleic acid sequence of SEQ ID NO: 29; and an M2 having a nucleic acid sequence of SEQ ID NO: 36;
an M1 having a nucleic acid sequence of SEQ ID NO: 29; and an M2 having a nucleic acid sequence of SEQ ID NO: 37;
an M1 having a nucleic acid sequence of SEQ ID NO: 29; and an M2 having a nucleic acid sequence of SEQ ID NO: 38;
an M1 having a nucleic acid sequence of SEQ ID NO: 29; and an M2 having a nucleic acid sequence of SEQ ID NO: 39;
an M1 having a nucleic acid sequence of SEQ ID NO: 29; and an M2 having a nucleic acid sequence of SEQ ID NO: 40;
an M1 having a nucleic acid sequence of SEQ ID NO: 29; and an M2 having a nucleic acid sequence of SEQ ID NO: 41;
an M1 having a nucleic acid sequence of SEQ ID NO: 29; and an M2 having a nucleic acid sequence of SEQ ID NO: 42;
an M1 having a nucleic acid sequence of SEQ ID NO: 29; and an M2 having a nucleic acid sequence of SEQ ID NO: 43;
an M1 having a nucleic acid sequence of SEQ ID NO: 30; and an M2 having a nucleic acid sequence of SEQ ID NO: 34;
an M1 having a nucleic acid sequence of SEQ ID NO: 30; and an M2 having a nucleic acid sequence of SEQ ID NO: 35;
an M1 having a nucleic acid sequence of SEQ ID NO: 30; and an M2 having a nucleic acid sequence of SEQ ID NO: 36;
an M1 having a nucleic acid sequence of SEQ ID NO: 30; and an M2 having a nucleic acid sequence of SEQ ID NO: 37;
an M1 having a nucleic acid sequence of SEQ ID NO: 30; and an M2 having a nucleic acid sequence of SEQ ID NO: 38;
an M1 having a nucleic acid sequence of SEQ ID NO: 30; and an M2 having a nucleic acid sequence of SEQ ID NO: 39;
an M1 having a nucleic acid sequence of SEQ ID NO: 30; and an M2 having a nucleic acid sequence of SEQ ID NO: 40;
an M1 having a nucleic acid sequence of SEQ ID NO: 30; and an M2 having a nucleic acid sequence of SEQ ID NO: 41;
an M1 having a nucleic acid sequence of SEQ ID NO: 30; and an M2 having a nucleic acid sequence of SEQ ID NO: 42;
an M1 having a nucleic acid sequence of SEQ ID NO: 30; and an M2 having a nucleic acid sequence of SEQ ID NO: 43;
an M1 having a nucleic acid sequence of SEQ ID NO: 31; and an M2 having a nucleic acid sequence of SEQ ID NO: 34;
an M1 having a nucleic acid sequence of SEQ ID NO: 31; and an M2 having a nucleic acid sequence of SEQ ID NO: 35;
an M1 having a nucleic acid sequence of SEQ ID NO: 31; and an M2 having a nucleic acid sequence of SEQ ID NO: 36;
an M1 having a nucleic acid sequence of SEQ ID NO: 31; and an M2 having a nucleic acid sequence of SEQ ID NO: 37;
an M1 having a nucleic acid sequence of SEQ ID NO: 31; and an M2 having a nucleic acid sequence of SEQ ID NO: 38;
an M1 having a nucleic acid sequence of SEQ ID NO: 31; and an M2 having a nucleic acid sequence of SEQ ID NO: 39;
an M1 having a nucleic acid sequence of SEQ ID NO: 31; and an M2 having a nucleic acid sequence of SEQ ID NO: 40;
an M1 having a nucleic acid sequence of SEQ ID NO: 31; and an M2 having a nucleic acid sequence of SEQ ID NO: 41;
an M1 having a nucleic acid sequence of SEQ ID NO: 31; and an M2 having a nucleic acid sequence of SEQ ID NO: 42;
an M1 having a nucleic acid sequence of SEQ ID NO: 31; and an M2 having a nucleic acid sequence of SEQ ID NO: 43;
an M1 having a nucleic acid sequence of SEQ ID NO: 32; and an M2 having a nucleic acid sequence of SEQ ID NO: 34;
an M1 having a nucleic acid sequence of SEQ ID NO: 32; and an M2 having a nucleic acid sequence of SEQ ID NO: 35;
an M1 having a nucleic acid sequence of SEQ ID NO: 32; and an M2 having a nucleic acid sequence of SEQ ID NO: 36;
an M1 having a nucleic acid sequence of SEQ ID NO: 32; and an M2 having a nucleic acid sequence of SEQ ID NO: 37;
an M1 having a nucleic acid sequence of SEQ ID NO: 32; and an M2 having a nucleic acid sequence of SEQ ID NO: 38;
an M1 having a nucleic acid sequence of SEQ ID NO: 32; and an M2 having a nucleic acid sequence of SEQ ID NO: 39;
an M1 having a nucleic acid sequence of SEQ ID NO: 32; and an M2 having a nucleic acid sequence of SEQ ID NO: 40;
an M1 having a nucleic acid sequence of SEQ ID NO: 32; and an M2 having a nucleic acid sequence of SEQ ID NO: 41;
an M1 having a nucleic acid sequence of SEQ ID NO: 32; and an M2 having a nucleic acid sequence of SEQ ID NO: 42;
an M1 having a nucleic acid sequence of SEQ ID NO: 32; and an M2 having a nucleic acid sequence of SEQ ID NO: 43;
an M1 having a nucleic acid sequence of SEQ ID NO: 33; and an M2 having a nucleic acid sequence of SEQ ID NO: 34;
an M1 having a nucleic acid sequence of SEQ ID NO: 33; and an M2 having a nucleic acid sequence of SEQ ID NO: 35;
an M1 having a nucleic acid sequence of SEQ ID NO: 33; and an M2 having a nucleic acid sequence of SEQ ID NO: 36;
an M1 having a nucleic acid sequence of SEQ ID NO: 33; and an M2 having a nucleic acid sequence of SEQ ID NO: 37;
an M1 having a nucleic acid sequence of SEQ ID NO: 33; and an M2 having a nucleic acid sequence of SEQ ID NO: 38;
an M1 having a nucleic acid sequence of SEQ ID NO: 33; and an M2 having a nucleic acid sequence of SEQ ID NO: 39;
an M1 having a nucleic acid sequence of SEQ ID NO: 33; and an M2 having a nucleic acid sequence of SEQ ID NO: 40;
an M1 having a nucleic acid sequence of SEQ ID NO: 33; and an M2 having a nucleic acid sequence of SEQ ID NO: 41;
an M1 having a nucleic acid sequence of SEQ ID NO: 33; and an M2 having a nucleic acid sequence of SEQ ID NO: 42; or
an M1 having a nucleic acid sequence of SEQ ID NO: 33; and an M2 having a nucleic acid sequence of SEQ ID NO: 43.

### Claim 48 (depends on 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47)

The cassette of any one of claims 35-47, wherein the donor DNA sequence is a target strand donor DNA sequence.

### Claim 49 (depends on 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48)

A retron donor DNA-guide polynucleotide comprising a retron transcript comprising the product of the cassette of any one of claims 35-48, and optionally a gRNA.

### Claim 50 (depends on 49)

The polynucleotide of claim 49, wherein the retron transcript and the gRNA are not linked together; or the retron transcript and the gRNA are linked together, such as part of the same transcript, or not part of the same contiguous transcript.

### Claim 51 (depends on 50)

The polynucleotide of claim 50, wherein the retron and gRNA are covalently linked together.

### Claim 52 (depends on 49, 50, 51)

The polynucleotide of any one of claims 49-51, wherein the retron transcript and the gRNA comprises a structured motif at a 5′ or a 3′ end of the retron-gRNA transcript, such as evoPreQ, tevopreQ mpKnot, or exoribonuclease-resistant RNA motif.

### Claim 53 (depends on 52)

The polynucleotide of claim 52, wherein the structured motif comprises a nucleic acid sequence selected from any one of SEQ ID NO: 75, 76, 77, 78, 79, 80, 81, or 82.

### Claim 54 (depends on 49, 50, 51, 52, 53)

The polynucleotide of any one of claims 49-53, wherein the retron transcript linked to the gRNA molecule comprises a formula A1-Rt-L1n-gRNA-A2, wherein:
(a) A1 is the structured motif, or is absent;
Rt is the retron transcript;
L1n is a nucleotide linker from about 5 to about 40, about 8 to about 35, about 9, or about 33 basepairs, or is absent; and
A2 is the structured motif, or is absent;
(b) A1 is the structured motif;
Rt is the retron transcript;
L1n is a nucleotide linker from about 5 to about 40, about 8 to about 35, about 9, or about 33 basepairs; and
A2 is absent; or
(c) A1 is absent;
Rt is the retron transcript;
L1 is a nucleotide linker from about 5 to about 40, about 8 to about 35, about 9, or about 33 base pairs; and
A2 is the structured motif.

### Claim 55 (depends on 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54)

A vector (e.g., plasmid, virus, and the like) comprising the cassette of any one of claims 35-48, or the polynucleotide of any one of claim 49-54.

### Claim 56

A polypeptide having the formula of: of (N1)q-C1-L1-(N2)qq-R1-(N3)qqq, wherein C1 is a nuclease, L1 is a peptide linker, R1 is a RT protein, and N1 and N2 are each independently, a NLS sequence, and wherein q, qq, or qqq, are each independently, 0, 1, 2, or 3.

### Claim 57 (depends on 56)

The polypeptide of claim 56, wherein the polypeptide has the formula of:
wherein:
each N1, N1A, N2, N3, or N3A is, independently, a NLS sequence;
each L1, L2, or L3 is independently, a linker amino acid sequence; and
wherein each NLS sequence is identical or different.

### Claim 58

A polypeptide comprising a SSAP, RT, and a nuclease, wherein:
the C-terminus of the RT is linked to the N-terminus of the nuclease, and the C-terminus of the nuclease is linked to the N-terminus of the SSAP; or
the N-terminus of the RT is linked to the C-terminus of the nuclease, and the N-terminus of the nuclease is linked to the C-terminus of the SSAP.

### Claim 59 (depends on 56, 57, 58)

A nucleic acid molecule encoding the polypeptide of any one of claims 56-58.

### Claim 60 (depends on 59)

A vector comprising the nucleic acid molecule of claim 59, wherein the vector is a plasmid, virus, RNA, mRNA, and the like.

### Claim 61 (depends on 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 56, 57, 58)

A cell comprising the cassette of any one of claims 35-48, the polynucleotide of any one of claim 49-54, or the polypeptide of any one of claim 56-58.

### Claim 62 (depends on 61)

The cell of claim 61, wherein the cell is a mammalian cell, such as a human cell.

### Claim 63 (depends on 61, 62)

The cell of claim 61 or 62, wherein the is cell is in a subject.
